Effects of <i>Lactobacillus rhamnosus</i> GG and <i>Bifidobacterium lactis</i> Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: protocol of a randomised controlled trial.

Abstract

Recent evidence has demonstrated that, among other factors, dysbiosis (imbalances in the composition and function of the gut microbiota) may be relevant in the development of type 1 diabetes (T1D). Thus, gut microbiota may be a target for improving outcomes in subjects with T1D. The aim of the study is to examine the effects of <i>Lactobacillus rhamnosus</i> GG and <i>Bifidobacterium lactis</i> Bb12 on beta-cell function in children with newly diagnosed T1D. A total of 96 children aged 8 to 17 years with newly diagnosed T1D, confirmed by clinical history and the presence of at least one positive autoantibody, will be enrolled in a double-blind, randomised, placebo-controlled trial in which they will receive <i>L. rhamnosus</i> GG and <i>B. lactis</i> Bb12 at a dose of 10⁹ colony-forming units or an identically appearing placebo, orally, once daily, for 6 months. The follow-up will be for 12 months. The primary outcome measures will be the area under the curve of the C-peptide level during 2-hour responses to a mixed meal. The Bioethics Committee approved the study protocol. The findings of this trial will be submitted to a peer-reviewed paediatric journal. Abstracts will be submitted to relevant national and international conferences. NCT03032354; Pre-results.